Identification
- Generic Name
- Chlorhexadol
- DrugBank Accession Number
- DB01534
- Background
Chlorhexadol is a sedative and hypnotic which is regulated in the United States as a Schedule III controlled substance. It is a derivative of chloral hydrate.
- Type
- Small Molecule
- Groups
- Experimental, Illicit
- Structure
Structure for Chlorhexadol (DB01534)
- Weight
- Average: 265.562
Monoisotopic: 264.008677467 - Chemical Formula
- C8H15Cl3O3
- Synonyms
- Chloralodol
- Chloralodolum
- Cloralodol
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Chloral hydrate has sedative/hypnotic activity which has been shown to extend the sleep of normal made adults via a dose-response relationship. [1]
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Chlorhexadol is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Chlorhexadol. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Chlorhexadol. Aclidinium Chlorhexadol may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Agomelatine The risk or severity of adverse effects can be increased when Chlorhexadol is combined with Agomelatine. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorhexadol. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Chlorhexadol. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorhexadol. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Chlorhexadol. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorhexadol. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Lora / Mecoral / Medodorm / Merchloral
Categories
- ATC Codes
- N05CC02 — Chloralodol
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tertiary alcohols. These are compounds in which a hydroxy group, -OH, is attached to a saturated carbon atom R3COH (R not H ).
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Alcohols and polyols
- Direct Parent
- Tertiary alcohols
- Alternative Parents
- Hemiacetals / Chlorohydrins / Organochlorides / Hydrocarbon derivatives / Alkyl chlorides
- Substituents
- Aliphatic acyclic compound / Alkyl chloride / Alkyl halide / Chlorohydrin / Halohydrin / Hemiacetal / Hydrocarbon derivative / Organochloride / Organohalogen compound / Tertiary alcohol
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W8RD4N93R2
- CAS number
- 3563-58-4
- InChI Key
- QVFWZNCVPCJQOP-UHFFFAOYSA-N
- InChI
- InChI=1S/C8H15Cl3O3/c1-5(4-7(2,3)13)14-6(12)8(9,10)11/h5-6,12-13H,4H2,1-3H3
- IUPAC Name
- 2-methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)pentan-2-ol
- SMILES
- CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
References
- General References
- CONDOURIS GA, BONNYCASTLE DD: A pharmacological investigation of the hypnotic action of a new derivative of chloral hydrate, chlorhexadol. Am J Med Sci. 1961 Nov;242:574-8. [Article]
- External Links
- KEGG Drug
- D07325
- PubChem Compound
- 19094
- PubChem Substance
- 46508125
- ChemSpider
- 18027
- ChEBI
- 135097
- ChEMBL
- CHEMBL2104116
- Wikipedia
- Chloralodol
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 103 °C PhysProp boiling point (°C) 304.7°Cat760mmHg Not Available - Predicted Properties
Property Value Source Water Solubility 1.24 mg/mL ALOGPS logP 2.34 ALOGPS logP 1.82 ChemAxon logS -2.3 ALOGPS pKa (Strongest Acidic) 9.67 ChemAxon pKa (Strongest Basic) -2.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 49.69 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 58.63 m3·mol-1 ChemAxon Polarizability 24.4 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9867 Blood Brain Barrier + 0.9769 Caco-2 permeable - 0.5191 P-glycoprotein substrate Non-substrate 0.6485 P-glycoprotein inhibitor I Non-inhibitor 0.8956 P-glycoprotein inhibitor II Non-inhibitor 0.8033 Renal organic cation transporter Non-inhibitor 0.956 CYP450 2C9 substrate Non-substrate 0.8184 CYP450 2D6 substrate Non-substrate 0.8683 CYP450 3A4 substrate Substrate 0.5052 CYP450 1A2 substrate Non-inhibitor 0.9172 CYP450 2C9 inhibitor Non-inhibitor 0.8425 CYP450 2D6 inhibitor Non-inhibitor 0.9166 CYP450 2C19 inhibitor Non-inhibitor 0.5114 CYP450 3A4 inhibitor Non-inhibitor 0.8803 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7975 Ames test Non AMES toxic 0.7245 Carcinogenicity Carcinogens 0.6919 Biodegradation Not ready biodegradable 0.9906 Rat acute toxicity 2.7114 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9798 hERG inhibition (predictor II) Non-inhibitor 0.9061
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at July 31, 2007 13:10 / Updated at June 12, 2020 16:51